These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31322555)

  • 21. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics.
    Al-Baradie RS
    Hum Antibodies; 2020; 28(4):259-272. PubMed ID: 32831197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Application of nanobody in cancer treatment].
    Wu Y; Hao X; Li M
    Sheng Wu Gong Cheng Xue Bao; 2017 Jul; 33(7):1085-1090. PubMed ID: 28869728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanobodies®: proficient tools in diagnostics.
    Huang L; Muyldermans S; Saerens D
    Expert Rev Mol Diagn; 2010 Sep; 10(6):777-85. PubMed ID: 20843201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanobodies in cancer.
    Verhaar ER; Woodham AW; Ploegh HL
    Semin Immunol; 2021 Feb; 52():101425. PubMed ID: 33272897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Progress in nanobody and its application in diagnosis].
    Kong Q; Yao Y; Chen R; Lu S
    Sheng Wu Gong Cheng Xue Bao; 2014 Sep; 30(9):1351-61. PubMed ID: 25720150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Research Progresses and Applications of Fluorescent Protein Antibodies: A Review Focusing on Nanobodies.
    Chen YL; Xie XX; Zhong N; Sun LC; Lin D; Zhang LJ; Weng L; Jin T; Cao MJ
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
    Ahadi M; Ghasemian H; Behdani M; Kazemi-Lomedasht F
    J Immunotoxicol; 2019 Dec; 16(1):34-42. PubMed ID: 30409071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation and characterization of nanobodies against rhGH expressed as sfGFP fusion protein.
    Abbady AQ; Al-Shemali R; Mir Assaad J; Murad H
    Gen Comp Endocrinol; 2014 Aug; 204():33-42. PubMed ID: 24859761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies.
    Bannas P; Well L; Lenz A; Rissiek B; Haag F; Schmid J; Hochgräfe K; Trepel M; Adam G; Ittrich H; Koch-Nolte F
    Contrast Media Mol Imaging; 2014; 9(2):135-42. PubMed ID: 24523058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-Neutralising Nanobodies Bind to a Conserved Pocket in the Hemagglutinin Stem Region Identified Using Yeast Display and Deep Mutational Scanning.
    Gaiotto T; Hufton SE
    PLoS One; 2016; 11(10):e0164296. PubMed ID: 27741319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanobodies: a promising approach to treatment of viral diseases.
    Minatel VM; Prudencio CR; Barraviera B; Ferreira RS
    Front Immunol; 2023; 14():1303353. PubMed ID: 38322011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A guide to: generation and design of nanobodies.
    Muyldermans S
    FEBS J; 2021 Apr; 288(7):2084-2102. PubMed ID: 32780549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploiting Nanobodies' Singular Traits.
    Ingram JR; Schmidt FI; Ploegh HL
    Annu Rev Immunol; 2018 Apr; 36():695-715. PubMed ID: 29490163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applications of nanobodies in plant science and biotechnology.
    Wang W; Yuan J; Jiang C
    Plant Mol Biol; 2021 Jan; 105(1-2):43-53. PubMed ID: 33037986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
    Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2559. PubMed ID: 30459772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Characterization of Nanobodies Targeting the Kupffer Cell.
    Zheng F; Zhou J; Ouyang Z; Zhang J; Wang X; Muyldermans S; Van Ginderachter J; Devoogdt N; Wen Y; Schoonooghe S; Raes G
    Front Immunol; 2021; 12():641819. PubMed ID: 33692811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy.
    Panikar SS; Banu N; Haramati J; Del Toro-Arreola S; Riera Leal A; Salas P
    J Control Release; 2021 Jun; 334():389-412. PubMed ID: 33964364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity Risk Profile of Nanobodies.
    Ackaert C; Smiejkowska N; Xavier C; Sterckx YGJ; Denies S; Stijlemans B; Elkrim Y; Devoogdt N; Caveliers V; Lahoutte T; Muyldermans S; Breckpot K; Keyaerts M
    Front Immunol; 2021; 12():632687. PubMed ID: 33767701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation and Screening of Antigen-Specific Nanobodies from Mammalian Cells Expressing the BCR Repertoire Library Using Droplet-Based Microfluidics.
    Lyu M; Shi X; Liu X; Liu Y; Zhu X; Liao L; Zhao H; Sun N; Wang S; Chen L; Fan L; Xu Q; Zhu Q; Gao K; Chen H; Zhu Y; Li Z; Guo W; Zheng Y; Gu Y; Liu L; Wang M; Liu Y
    Anal Chem; 2022 Jun; 94(22):7970-7980. PubMed ID: 35604850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.